用于性侵犯后暴露后预防的复方比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺：一项回顾性真实世界研究。
Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.
作者信息
Teresita de Jesús Cabrera-López, Edgar Pérez-Barragán, Carlos Ruben Nava-Campos, Marla Toiber-Rodríguez, Juan Carlos Rodríguez-Aldama, Raúl Adrián Cruz-Flores, Andrea González-Rodríguez
机构信息
Department of Gynecology and Care for Victims of Sexual Assault, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico.
Department of Infectious Diseases, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico.
出版信息
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae436. doi: 10.1093/ofid/ofae436. eCollection 2024 Aug.
Abstract
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
摘要
我们报告了比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺用于性侵犯案件中非职业性暴露后预防的经验。在2021年6月至2023年10月期间，39人完成了28天的随访；41%的人出现了一些副作用，1人因皮疹而停药。在随访期间，没有个体血清转化为HIV。
相似文献
1
Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study.用于性侵犯后暴露后预防的复方比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺：一项回顾性真实世界研究。
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae436. doi: 10.1093/ofid/ofae436. eCollection 2024 Aug.
2
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1489）：一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
3
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯复方片剂与多替拉韦加拉米夫定和丙酚替诺福韦二吡呋酯用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1490）：一项随机、双盲、多中心、3 期、非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
4
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.在病毒学抑制的 HIV 儿童患者（年龄 2 岁及以上）中，双替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯复方制剂的药代动力学和安全性：一项 2/3 期、开放标签、单臂研究。
Lancet HIV. 2024 May;11(5):e300-e308. doi: 10.1016/S2352-3018(23)00327-2. Epub 2024 Apr 12.
5
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.固定剂量复方比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与含多替拉韦方案治疗初治人类免疫缺陷病毒 1 型感染：两项随机、双盲、多中心、Ⅲ期、非劣效性临床试验的 144 周结果。
Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0.
6
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.固定剂量复方双替格瑞韦、恩曲他滨和替诺福韦艾拉酚胺在青少年和儿童 HIV 感染者中的应用：一项单臂、开放标签、多中心、2/3 期临床试验的第 48 周结果。
Lancet Child Adolesc Health. 2021 Sep;5(9):642-651. doi: 10.1016/S2352-4642(21)00165-6. Epub 2021 Jul 22.
7
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.每日一次贝曲沙秦、恩曲他滨和替诺福韦艾拉酚胺用于性暴露后预防的安全性和耐受性。
J Acquir Immune Defic Syndr. 2022 May 1;90(1):27-32. doi: 10.1097/QAI.0000000000002912.
8
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
9
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、恩曲他滨和富马酸替诺福韦二吡呋酯用于初治HIV-1和乙型肝炎合并感染（ALLIANCE）：一项双盲、多中心、随机对照3期非劣效性试验。
Lancet HIV. 2023 Oct;10(10):e640-e652. doi: 10.1016/S2352-3018(23)00151-0. Epub 2023 Jul 23.
10
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.对于接受比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺治疗且病毒学抑制的成人HIV-1感染者，改用每日一次的固定剂量多拉韦林（100毫克）与艾斯拉维（0·75毫克）联合治疗：一项3期随机对照双盲非劣效性试验的48周结果。
Lancet HIV. 2024 Jun;11(6):e357-e368. doi: 10.1016/S2352-3018(24)00030-4. Epub 2024 May 8.
本文引用的文献
1
An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1.一项评估比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂用于潜在人类免疫缺陷病毒 1 暴露后预防的开放性标签安全性和耐受性的研究。
Chin Med J (Engl). 2022 Nov 20;135(22):2725-2729. doi: 10.1097/CM9.0000000000002494.
2
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.每日一次贝曲沙秦、恩曲他滨和替诺福韦艾拉酚胺用于性暴露后预防的安全性和耐受性。
J Acquir Immune Defic Syndr. 2022 May 1;90(1):27-32. doi: 10.1097/QAI.0000000000002912.
3
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.两剂恩曲他滨/替诺福韦艾拉酚胺加比克替拉韦预防可保护猕猴免受猴免疫缺陷病毒感染。
J Antimicrob Chemother. 2021 Feb 11;76(3):692-698. doi: 10.1093/jac/dkaa476.
4
Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58).抗逆转录病毒初治的 HIV-1 感染者中，比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗对人类免疫缺陷病毒（HIV）RNA 衰减动力学和比克替拉韦在生殖道和直肠中的分布：西班牙艾滋病毒/艾滋病研究网络（HIV/AIDS Research Network，PreEC/RIS 58）研究
Clin Infect Dis. 2021 Oct 5;73(7):e1991-e1999. doi: 10.1093/cid/ciaa1416.
5
Post-exposure prophylaxis for HIV infection in sexual assault victims.HIV 感染后暴露于性侵犯受害者的预防措施。
HIV Med. 2020 Jan;21(1):43-52. doi: 10.1111/hiv.12797. Epub 2019 Oct 11.
6
Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016.公告：更新后的艾滋病病毒经性、注射毒品或其他非职业暴露后抗逆转录病毒预防治疗指南-美国，2016 年。
MMWR Morb Mortal Wkly Rep. 2016 May 6;65(17):458. doi: 10.15585/mmwr.mm6517a5.
7
World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach.世界卫生组织关于艾滋病毒暴露后预防的指南：公共卫生方法建议。
Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S161-4. doi: 10.1093/cid/civ068.
8
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.用于降低艾滋病毒感染母婴传播风险的抗逆转录病毒药物。
Cochrane Database Syst Rev. 2011 Jul 6(7):CD003510. doi: 10.1002/14651858.CD003510.pub3.
9
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.美国性接触、注射吸毒或其他非职业性接触艾滋病毒后的抗逆转录病毒暴露后预防：美国卫生与公众服务部的建议
MMWR Recomm Rep. 2005 Jan 21;54(RR-2):1-20.
10
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.医护人员经皮暴露后HIV血清转化的病例对照研究。疾病控制与预防中心针刺伤监测小组。
N Engl J Med. 1997 Nov 20;337(21):1485-90. doi: 10.1056/NEJM199711203372101.
Zotero 插件